Farmingdale, NY – According to filings with the U.S. Securities and Exchange Commission, DepYmed is raising $15,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Andreas Grill played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DepYmed

DepYmed Inc., is a New York based cancer and rare disease therapeutic development company. DepYmed is currently developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome. In addition to PTP1B inhibitors, DepYmed has developed a portfolio of novel small molecules with copper chelating properties which can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer.

To learn more about DepYmed, visit http://depymedinc.com/

Contact:
Andreas Grill, President and Chief Executive Officer
631-686-5802
https://www.linkedin.com/in/andreas-grill-2845053/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved